Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia

Nobuaki Mori; Mitsuya Katayama; Shigenari Nukaga

doi:10.1016/j.jmii.2020.09.003

Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia

J Microbiol Immunol Infect. 2021 Feb;54(1):109-112. doi: 10.1016/j.jmii.2020.09.003. Epub 2020 Oct 5.

Authors

Nobuaki Mori¹, Mitsuya Katayama², Shigenari Nukaga³

Affiliations

¹ Department of General Internal Medicine and Infectious Diseases, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan. Electronic address: nobuaki.m@icloud.com.
² Department of General Internal Medicine and Infectious Diseases, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan.
³ Department of Respiratory Medicine, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan.

Abstract

No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.

Keywords: Azithromycin; COVID-19; Ciclesonide; Hydroxychloroquine; Pneumonia; Reverse transcription-PCR; SARS-CoV-2; Therapy.

MeSH terms

Aged
Antiviral Agents / therapeutic use*
Azithromycin / therapeutic use*
COVID-19 / epidemiology
COVID-19 Drug Treatment*
Drug Therapy, Combination
Female
Humans
Hydroxychloroquine / therapeutic use*
Liver / drug effects
Male
Middle Aged
Pregnenediones / therapeutic use*
SARS-CoV-2 / drug effects
Tokyo / epidemiology

Substances

Antiviral Agents
Pregnenediones
Hydroxychloroquine
Azithromycin
ciclesonide